Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Aug;15(8):740-742.
doi: 10.1038/cmi.2017.162. Epub 2018 Feb 5.

Predictive immune biomarkers: an unattainable chimera?

Anna Maria Trotta  1 , Roberto Pacelli  2 , Stefania Scala  3
Affiliations
Comment

Predictive immune biomarkers: an unattainable chimera?

Anna Maria Trotta et al. Cell Mol Immunol. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immune biomarker identification: key points in the process. (a) Culture cells from lymph nodes derived from stage III melanoma patients. Schematic of tumor and tumor microenvironment. (b) Table of the treatments to which the cells in a were exposed. (c) Identification of parameters that discriminate patients as ‘Responder’ vs ‘Non-responders’ to anti-PD-1, anti-CTLA-4 and both among the conditions evaluated in b. (d) Retrospective validation of the parameters identified in c in the blood of resected stage IIIc and IV melanoma patients from a phase 2 adjuvant trial of ipilimumab plus nivolumab.
See this image and copyright information in PMC

Comment on

  • Predictors of responses to immune checkpoint blockade in advanced melanoma.
    Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Jacquelot N, et al. Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2. Nat Commun. 2017. PMID: 28928380 Free PMC article.

References

    1. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723. doi: 10.1016/j.cell.2017.01.017. - DOI - PMC - PubMed
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596. - DOI - PMC - PubMed
    1. Bates SE. Refining immunotherapy approvals. Clin Cancer Res. 2017;23:4948–4949. doi: 10.1158/1078-0432.CCR-17-2025. - DOI - PubMed
    1. Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The challenge for development of valuable immuno-oncology biomarkers. Clin Cancer Res. 2017;23:4970–4979. doi: 10.1158/1078-0432.CCR-16-3063. - DOI - PMC - PubMed
    1. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi: 10.1186/1479-5876-9-204. - DOI - PMC - PubMed

LinkOut - more resources